HeartCare Launches 8F Vascular Closure Device – Xinwei Maihe® Hemostatic System Expands Portfolio with New Size

HeartCare^®Since its launch in China in February 2022, the occlusion and hemostasis system has rapidly become an outstanding representative of domestically produced occlusion and hemostasis systems, thanks to its advanced design concept and excellent clinical performance. The system has not only gained widespread acclaim in the mainland market but also successfully obtained registration approval from the Thai Food and Drug Administration (Thai FDA) in April 2023. In 2024, it received consecutive approvals from Belarus, Taiwan, China, Ecuador, and other regions, further enhancing its international influence.

HeartCare^®The occlusion hemostasis system is mainly used for occlusion and hemostasis in patients with femoral artery puncture. Its applications cover multiple fields such as neurointervention, peripheral intervention, and cardiac intervention, providing an efficient and convenient solution for clinicians managing puncture sites.

In response to clinical pain points, HeartCare always upholds the spirit of active exploration and bold innovation.The addition of the 8F specification this time is based on a deep understanding and precise grasp of the actual clinical needs in China. From now on, operators no longer need to worry about how to block the 8F puncture sheath; they can simply choose based on the patient's actual condition. It is simpler, easier to use, effective, and reliable.